SCHEMBL23155302

SCHEMBL23155302

c1ccc(-c2ccc(N(c3ccc(-c4ccc5c(c4)-c4c6cccc4-c4cccc-5c4-c4ccccc4-6)cc3)c3cccc4oc5ccccc5c34)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ APAF1 O14727 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ PTBP1 P26599 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ GALK1 P51570 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ SMAD3 P84022 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ PLA2G2A P14555 4/20 0.34
▸ PLA2G4A P47712 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23155123 0.98 PLA2G2A (0.32) NPC1RAB9ASMN1; SMN2MEN1APAF1
SCHEMBL23155234 0.95 PLA2G2A (0.32) NPC1RAB9ASMN1; SMN2PLA2G2APLA2G4A
SCHEMBL23155322 0.94 PLA2G2A (0.33) NPC1RAB9ASMN1; SMN2MEN1APAF1
SCHEMBL23155282 0.89 ALOX5 (0.32) ALOX5
SCHEMBL25608147 0.89 PLA2G2A (0.33) NPC1RAB9ASMN1; SMN2MAPTL3MBTL1
SCHEMBL21141183 0.88 NPC1 (0.35) NPC1RAB9ASMN1; SMN2MEN1APAF1
SCHEMBL25580624 0.88 CDC14B (0.33) NPC1RAB9ASMN1; SMN2MAPTPLA2G2A
SCHEMBL24999257 0.88 PLA2G2A (0.37) NPC1RAB9ASMN1; SMN2MEN1APAF1
SCHEMBL21141187 0.88 NPC1 (0.35) NPC1RAB9ASMN1; SMN2MEN1APAF1
SCHEMBL25580508 0.88 CDC14B (0.33) NPC1RAB9ASMN1; SMN2MAPTPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11594684-B2 Condensed-cyclic compound and organic light emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2023-02-28 — — US disclosed
EP-3799144-B1 CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO LTD (KR) 2022-06-01 — — EP disclosed
US-20210098700-A1 CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2021-04-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11594684-B2 Condensed-cyclic compound and organic light emitting device including the same CRY1, SMCHD1, CXCR1 NPC1 2344/4885RAB9A 2552/4885SMN1; SMN2 2950/4885
US-20210098700-A1 CONDENSED-CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME CRY1, SMCHD1, CXCR1 NPC1 2344/4885RAB9A 2552/4885SMN1; SMN2 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback